Corebridge Financial Inc. Has $10.50 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Corebridge Financial Inc. decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 134,999 shares of the medical device company’s stock after selling 6,827 shares during the quarter. Corebridge Financial Inc.’s holdings in DexCom were worth $10,499,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of DXCM. Versant Capital Management Inc acquired a new position in shares of DexCom in the 4th quarter valued at about $25,000. Private Trust Co. NA grew its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. TD Private Client Wealth LLC increased its stake in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after buying an additional 167 shares during the period. Larson Financial Group LLC lifted its position in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after buying an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter valued at $38,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Morgan Stanley upped their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Canaccord Genuity Group lifted their price target on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and boosted their price target for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Cfra Research raised shares of DexCom to a “hold” rating in a research report on Friday, March 21st. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

Insiders Place Their Bets

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael Jon Brown sold 13,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the transaction, the executive vice president now owns 105,602 shares of the company’s stock, valued at $7,432,268.76. This trade represents a 10.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock worth $8,044,178 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Down 1.9 %

DXCM stock opened at $72.13 on Thursday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $141.99. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market cap of $28.19 billion, a PE ratio of 50.44, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The business’s 50-day simple moving average is $82.96 and its 200 day simple moving average is $77.07.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.